Section 6 of 6
References
256 sources
- Abraxane prescribing information (2020) (opens in a new tab)
- Afinitor prescribing information (2026) (opens in a new tab)
- Allen (2010) (opens in a new tab)
- Allison et al. (2020) (opens in a new tab)
- American Cancer Society Breast Cancer Facts and Figures (2024) (opens in a new tab)
- American Cancer Society Cancer Facts and Figures (2026) (opens in a new tab)
- American Cancer Society Key Statistics for Breast Cancer (2026) (opens in a new tab)
- Andrade et al. (2024) (opens in a new tab)
- André et al. (2019) (opens in a new tab)
- André et al. (2021) (opens in a new tab)
- Aromasin prescribing information (2024) (opens in a new tab)
- AstraZeneca SERENA-4 update announcement (2026) (opens in a new tab)
- AstraZeneca Truqap blister pack availability notice (2024) (opens in a new tab)
- Atre et al. (2024) (opens in a new tab)
- Bardia et al. (2024a) (opens in a new tab)
- Bardia et al. (2024b) (opens in a new tab)
- Bardia et al. (2025) (opens in a new tab)
- Barratt et al. (2026) (opens in a new tab)
- Baselga et al. (2012) (opens in a new tab)
- Behan et al. (2025) (opens in a new tab)
- Bello et al. (2026) (opens in a new tab)
- Benvenuti et al. (2023) (opens in a new tab)
- Bhave et al. (2024) (opens in a new tab)
- Bidard et al. (2022) (opens in a new tab)
- Bidard et al. (2025) (opens in a new tab)
- Borges et al. (2023a) (opens in a new tab)
- Borges et al. (2023b) (opens in a new tab)
- Borges et al. (2024a) (opens in a new tab)
- Borges et al. (2024b) (opens in a new tab)
- Bramley et al. (2016) (opens in a new tab)
- Brett et al. (2021) (opens in a new tab)
- Brufsky et al. (2024) (opens in a new tab)
- Burstein et al. (2021) (opens in a new tab)
- Burstein et al. (2023) (opens in a new tab)
- Burstein et al. (2024) (opens in a new tab)
- Cabel et al. (2026) (opens in a new tab)
- Cadirov et al. (2025) (opens in a new tab)
- CADTH capivasertib reimbursement recommendation (2024) (opens in a new tab)
- Campone et al. (2025) (opens in a new tab)
- Cardoso et al. (2024) (opens in a new tab)
- Cardoso et al. (2026) (opens in a new tab)
- Celcuity Form 10-Q (2026) (opens in a new tab)
- Chan et al. (2023a) (opens in a new tab)
- Chan et al. (2023b) (opens in a new tab)
- Chan et al. (2023c) (opens in a new tab)
- Chan et al. (2024) (opens in a new tab)
- Chandarlapaty et al. (2016) (opens in a new tab)
- Ciruelos et al. (2021) (opens in a new tab)
- Cleeland et al. (2014) (opens in a new tab)
- ClinicalTrials.gov NCT04505826 (opens in a new tab)
- ClinicalTrials.gov NCT04505826 results (opens in a new tab)
- ClinicalTrials.gov NCT05266105 (opens in a new tab)
- ClinicalTrials.gov NCT05508906 (opens in a new tab)
- ClinicalTrials.gov NCT06016738 (opens in a new tab)
- ClinicalTrials.gov NCT07085767 (opens in a new tab)
- CMS ADLT list (2026) (opens in a new tab)
- CMS Clinical Laboratory Fee Schedule (2026) (opens in a new tab)
- CMS Clinical Laboratory Fee Schedule file 26CLABQ4 (2026) (opens in a new tab)
- CMS Enhancing Oncology Model FAQ (2026) (opens in a new tab)
- CMS National Coverage Determination 90.2 (2020) (opens in a new tab)
- CMS Quality ID 047 (2026) (opens in a new tab)
- CMS Quality ID 143 (2026) (opens in a new tab)
- CMS Quality ID 144 (2026) (opens in a new tab)
- CMS Quality ID 453 (2026) (opens in a new tab)
- CMS Quality ID 457 (2026) (opens in a new tab)
- Comerford et al. (2025) (opens in a new tab)
- Cong et al. (2022) (opens in a new tab)
- Cortes et al. (2011) (opens in a new tab)
- Curigliano et al. (2026a) (opens in a new tab)
- Curigliano et al. (2026b) (opens in a new tab)
- Daily et al. (2021) (opens in a new tab)
- Datroway prescribing information (2026) (opens in a new tab)
- de Azambuja et al. (2026) (opens in a new tab)
- Dilawari et al. (2024) (opens in a new tab)
- Dilawari et al. (2025) (opens in a new tab)
- Eli Lilly and Company Inluriyo WAC disclosure (2025) (opens in a new tab)
- Enhertu prescribing information (2026) (opens in a new tab)
- Etcamah prescribing information (2026) (opens in a new tab)
- EU CTIS 2023-505871-63-00 (opens in a new tab)
- Faslodex prescribing information (2021) (opens in a new tab)
- FDA (2018) (opens in a new tab)
- FDA camizestrant approval notice (2026) (opens in a new tab)
- FDA gedatolisib approval notice (2026) (opens in a new tab)
- FDA Guardant360 CDx SSED S021 (2025) (opens in a new tab)
- FDA imlunestrant and abemaciclib approval notice (2026) (opens in a new tab)
- FDA imlunestrant approval notice (2025) (opens in a new tab)
- FDA vepdegestrant approval notice (2026) (opens in a new tab)
- Flavin et al. (2026) (opens in a new tab)
- Franklin et al. (2024) (opens in a new tab)
- Fribbens et al. (2016) (opens in a new tab)
- Gallicchio et al. (2022) (opens in a new tab)
- Gauthier et al. (2018) (opens in a new tab)
- Giaquinto et al. (2024) (opens in a new tab)
- Giuliano et al. (2019) (opens in a new tab)
- Gogate et al. (2021) (opens in a new tab)
- Goyal et al. (2019) (opens in a new tab)
- Goyal et al. (2021) (opens in a new tab)
- Gradishar et al. (2026) (opens in a new tab)
- Greer et al. (2020) (opens in a new tab)
- Gupta et al. (2025) (opens in a new tab)
- Halaven prescribing information (2022) (opens in a new tab)
- Hamilton et al. (2022) (opens in a new tab)
- Hamilton et al. (2025) (opens in a new tab)
- Hanker et al. (2020) (opens in a new tab)
- Hao et al. (2016) (opens in a new tab)
- Henry et al. (2022) (opens in a new tab)
- Howlader et al. (2018) (opens in a new tab)
- Hurvitz et al. (2026) (opens in a new tab)
- Inluriyo prescribing information (2026) (opens in a new tab)
- International Agency for Research on Cancer GLOBOCAN breast fact sheet (2026) (opens in a new tab)
- Irvin et al. (2011) (opens in a new tab)
- Itovebi prescribing information (2026) (opens in a new tab)
- Jaber Chehayeb et al. (2022) (opens in a new tab)
- Jeselsohn et al. (2015) (opens in a new tab)
- Jhaveri et al. (2025a) (opens in a new tab)
- Jhaveri et al. (2025b) (opens in a new tab)
- Jhaveri et al. (2026a) (opens in a new tab)
- Jhaveri et al. (2026b) (opens in a new tab)
- Kalinsky et al. (2023) (opens in a new tab)
- Kalinsky et al. (2025) (opens in a new tab)
- Kalinsky et al. (2026) (opens in a new tab)
- Kamal et al. (2017) (opens in a new tab)
- Kashiwa et al. (2026) (opens in a new tab)
- Kaufman et al. (2015) (opens in a new tab)
- Kuksis et al. (2021) (opens in a new tab)
- Lambert et al. (2024) (opens in a new tab)
- Lang et al. (2024) (opens in a new tab)
- Liang et al. (2026) (opens in a new tab)
- Liao et al. (2026) (opens in a new tab)
- Lin et al. (2023) (opens in a new tab)
- Lin et al. (2024) (opens in a new tab)
- Lin et al. (2025a) (opens in a new tab)
- Lin et al. (2025b) (opens in a new tab)
- Litton et al. (2018) (opens in a new tab)
- Litton et al. (2020) (opens in a new tab)
- Lloyd et al. (2006) (opens in a new tab)
- Lloyd et al. (2022) (opens in a new tab)
- Lloyd et al. (2024) (opens in a new tab)
- Lloyd et al. (2026a) (opens in a new tab)
- Lloyd et al. (2026b) (opens in a new tab)
- Lord et al. (2022) (opens in a new tab)
- Lynparza prescribing information (2025) (opens in a new tab)
- Mariotto et al. (2017) (opens in a new tab)
- Mariotto et al. (2020) (opens in a new tab)
- Martin et al. (2022) (opens in a new tab)
- Mayer et al. (2024) (opens in a new tab)
- Mayer et al. (2026a) (opens in a new tab)
- Mayer et al. (2026b) (opens in a new tab)
- Meisel et al. (2026) (opens in a new tab)
- Mertz et al. (2022) (opens in a new tab)
- Modi et al. (2022) (opens in a new tab)
- Modi et al. (2025) (opens in a new tab)
- Moy et al. (2021) (opens in a new tab)
- Moy et al. (2022) (opens in a new tab)
- Moy et al. (2023) (opens in a new tab)
- National Cancer Institute Breast Cancer Treatment PDQ (2025) (opens in a new tab)
- National Cancer Institute Metastatic Cancer (2026) (opens in a new tab)
- NCI Thesaurus (2026) (opens in a new tab)
- Neuss et al. (2016) (opens in a new tab)
- Ng et al. (2025) (opens in a new tab)
- Nguyen and Mital (2025) (opens in a new tab)
- Nguyen and Mital (2026) (opens in a new tab)
- NICE TA1036 committee discussion (2025) (opens in a new tab)
- NICE TA1036 recommendation (2025) (opens in a new tab)
- NICE TA1168 terminated appraisal (2026) (opens in a new tab)
- Nsubayi et al. (2026) (opens in a new tab)
- Okeke et al. (2025) (opens in a new tab)
- Olema Oncology AACR 2026 preclinical data announcement (2026) (opens in a new tab)
- Olema Oncology corporate name change announcement (2026) (opens in a new tab)
- Olema Oncology corporate presentation (2026) (opens in a new tab)
- Olema Oncology dose selection announcement (2025) (opens in a new tab)
- Olema Oncology ESMO 2025 ribociclib results announcement (2025) (opens in a new tab)
- Olema Oncology Fast Track designation announcement (2022) (opens in a new tab)
- Olema Oncology first quarter 2026 results announcement (2026) (opens in a new tab)
- Olema Oncology Form 10-K (2026) (opens in a new tab)
- Olema Oncology Form 10-Q (2026) (opens in a new tab)
- Olema Oncology fourth quarter and full year 2025 results announcement (2026) (opens in a new tab)
- Olema Oncology Novartis collaboration expansion announcement (2023) (opens in a new tab)
- Olema Oncology Novartis OPERA-02 agreement announcement (2024) (opens in a new tab)
- Olema Oncology Pfizer atirmociclib agreement announcement (2025) (opens in a new tab)
- Olema Oncology phase 2 monotherapy results announcement (2023) (opens in a new tab)
- Olema Oncology SABCS 2023 combination results announcement (2023) (opens in a new tab)
- Olema Oncology SABCS 2024 announcement (2024) (opens in a new tab)
- Olema Oncology SABCS 2026 presentations announcement (2026) (opens in a new tab)
- Olema Oncology second quarter 2025 results announcement (2025) (opens in a new tab)
- Olema Oncology second quarter 2026 results announcement (2026) (opens in a new tab)
- Olema Oncology third quarter 2025 results announcement (2025) (opens in a new tab)
- Olema Oncology third quarter 2026 results announcement (2026) (opens in a new tab)
- Oliveira et al. (2024a) (opens in a new tab)
- Oliveira et al. (2024b) (opens in a new tab)
- OP-1250-001 protocol (2022) (opens in a new tab)
- OP-1250-001 statistical analysis plan (2024) (opens in a new tab)
- Orserdu prescribing information (2026) (opens in a new tab)
- Pan et al. (2017) (opens in a new tab)
- Parisian et al. (2024) (opens in a new tab)
- Patel et al. (2021) (opens in a new tab)
- Pezzolato et al. (2023) (opens in a new tab)
- Piccart et al. (2014) (opens in a new tab)
- Piqray prescribing information (2026) (opens in a new tab)
- Pistilli et al. (2024) (opens in a new tab)
- Pistilli et al. (2025) (opens in a new tab)
- Pistilli et al. (2026a) (opens in a new tab)
- Pistilli et al. (2026b) (opens in a new tab)
- Revtorpyk prescribing information (2026) (opens in a new tab)
- Reyes et al. (2019) (opens in a new tab)
- Robson et al. (2017) (opens in a new tab)
- Robson et al. (2019) (opens in a new tab)
- Roche giredestrant New Drug Application acceptance announcement (2026) (opens in a new tab)
- Rocque et al. (2020) (opens in a new tab)
- Rocque et al. (2025) (opens in a new tab)
- Rosenzweig et al. (2019) (opens in a new tab)
- Royce et al. (2025) (opens in a new tab)
- Rugo et al. (2022) (opens in a new tab)
- Rugo et al. (2023) (opens in a new tab)
- Rugo et al. (2024) (opens in a new tab)
- Rugo et al. (2025) (opens in a new tab)
- Rugo et al. (2026) (opens in a new tab)
- Sammons et al. (2025) (opens in a new tab)
- Schiavon et al. (2015) (opens in a new tab)
- SEER Cancer Stat Facts Female Breast Cancer (2026) (opens in a new tab)
- SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026) (opens in a new tab)
- Shah et al. (2024) (opens in a new tab)
- Siegel et al. (2024) (opens in a new tab)
- Sorensen et al. (2012) (opens in a new tab)
- Sun et al. (2025) (opens in a new tab)
- Sung et al. (2026) (opens in a new tab)
- Talzenna prescribing information (2026) (opens in a new tab)
- Tolaney et al. (2025) (opens in a new tab)
- Tolaney et al. (2026) (opens in a new tab)
- Tolosa et al. (2026) (opens in a new tab)
- Toy et al. (2013) (opens in a new tab)
- Trodelvy prescribing information (2026) (opens in a new tab)
- Truqap prescribing information (2026) (opens in a new tab)
- Tung et al. (2020) (opens in a new tab)
- Turner et al. (2023) (opens in a new tab)
- Turner et al. (2024) (opens in a new tab)
- Twelves et al. (2014) (opens in a new tab)
- Van Poznak et al. (2017) (opens in a new tab)
- Veppanu prescribing information (2026) (opens in a new tab)
- Vermont Attorney General Orserdu report (2023) (opens in a new tab)
- Verzenio prescribing information (2026) (opens in a new tab)
- Wan et al. (2013) (opens in a new tab)
- Waters et al. (2024) (opens in a new tab)
- Wheeler et al. (2023) (opens in a new tab)
- WHO Proposed INN List 128 (2022) (opens in a new tab)
- WHO Recommended INN List 90 (2023) (opens in a new tab)
- Will et al. (2023) (opens in a new tab)
- Wolff et al. (2023) (opens in a new tab)
- Wood et al. (2017) (opens in a new tab)
- Wortelboer et al. (2025) (opens in a new tab)
- Wortelboer et al. (2026) (opens in a new tab)
- Wu et al. (2023) (opens in a new tab)
- Xeloda prescribing information (2025) (opens in a new tab)
- Yin et al. (2026) (opens in a new tab)
- Zeng et al. (2023) (opens in a new tab)
- Zhang et al. (2018) (opens in a new tab)